Phase II Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease

Inclusion Criteria:

- Patients must have lymphocyte predominant Hodgkin's disease that is
of B-cell lineage and expresses the CD 20 antigen. Patients are eligible with either
untreated disease or refractory/relapsed disease.

- Patients must be >= 3 years.

- Patients must have a performance status of 0-2.

- Patients must have an ANC > 1500/ml and a platelet count > 50,000/ml.

- A biopsy or fine needle aspirate sample must show expression of the CD20 antigen on
the L adnH cells.

- Patients must have measurable disease (at least one tumor mass measuring >1.0 cm in
largest dimension).

- Patients must have no evidence of active infection.

- Patients must read and sign IRB approved informed consent.

- Adequate renal function as indicated by serum creatinine (Cr) < 1.5X the upper limit
of normal.

- Adequate liver function as indicated by alkaline phosphatase, bilirubin, AST, and ALT
< 2X upper limit of normal unless related to primary disease.

- Patients at high risk of HBV infection should be screened prior to enrollment.

Exclusion Criteria:- Concomitant or recent treatment with radiotherapy or chemotherapy.
Four weeks must pass from radiotherapy or cytotoxic therapy to enroll (six weeks for
nitrosourea compounds).

- Major surgery, other than diagnostic surgery, within 4 weeks.

- Female patients must be of non-childbearing potential or using adequate contraception
with a negative pregnancy test at study entry.

- Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled
bacterial, viral, or fungal infections), or other conditions which, in the opinion of
the investigator and/or sponsor, would compromise other protocol objectives.

- Treatment with an investigational drug within 30 days or 5 half-lives (of the study
drug with the longest half-life) prior to entry into the study, whichever is longer.

- Evidence of other active malignancies other than cured carcinomas in situ of the
cervix or basal cell carcinoma of the skin.

- Life expectancy<= 12 weeks.

- Concurrent treatment with prednisone or other systemic steroid medication.

- Active HBV infection or hepatitis.